Platinum-resistant Ovarian Cancer Recruiting Phase 2 Trials for Luveltamab tazevibulin (DB17563)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs